Oukangweishi Biotech announced that in June 2026, the marketing registration application for Shishu's new drug was approved by the State Drug Administration; the current dexamethasone drug registration application has been accepted by the Drug Evaluation Center of the State Drug Administration as a category 4 chemicals, and has applied for inclusion in the list of priority review varieties and completed the publicity process.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.